The data sent to record-high stocks have shown that the vaccine for COVID-19 is about 90% effective on Coronavirus.
The data for safety is still to come in this month later, so they’re waiting for it.
New York: After developing the vaccine by BioNTech and Pfizer Inc, the work to be distributed to the experimental COVID-19 vaccine. Earlier on Monday, they announced the successful news and further said that it would not cone to the local pharmacies or general ones any before.
Amesh Adalja, who is the senior scholar for Health Security at Johns Hopkins Center, said: “The cold chain is going to be one of the most challenging aspects of the delivery of this vaccination.”
“This will be a challenge in all settings because hospitals, even in big cities, do not have storage facilities for a vaccine at that ultra-low temperature.”
The Mayo Clinic, which is also in the prestigious U.S. hospitals at Minnesota in Rochester, said that it doesn’t have that capability currently.
Dr. Gregory Poland, the vaccine researcher and a virologist, said: “We’re talking about a vaccine that needs storage at minus 70 or 80. That’s a huge logistical issue not only in the U.S. but outside the Western world.”
“We’re a major medical center, and we don’t have storage capacity like this. That will be true for everybody. This is a logistical obstacle.”
The executive director from the “Association of Immunization Managers” who handle vaccines said: “If Pfizer’s is the only vaccine to be authorized in the next few months, we do worry about equity when it comes to spreading it to rural areas.”
Stefan mentioned: “I think it will be difficult, but based on the task and how important it is, people will do the best to their ability to make that happen.”